President Trump announces 100% tariffs on movies made outside the US, potentially impacting the Indian film industry. The move follows similar tariffs on pharmaceutical products.
Delhi-based pharma major Mankind Pharma on Wednesday announced a collaboration with OpenAI to institutionalise artificial intelligence (AI) across its value chain, making it one of the first few Indian pharmaceutical companies to fully integrate advanced AI into its core operations.
Prices for Indian consumers are expected to come down significantly from the current Rs 17,000-Rs 26,000 monthly.
Credit quality of Indian corporate is expected to be stable in the second half of the current financial year (H2FY26), supported by easing monetary cycle, and declining inflation, coupled with income-tax relief and rationalisation of the goods and service tax (GST) rates, among others.
A generic cough syrup supplied to the Rajasthan government has been linked to the deaths of two children and others falling sick in the state, prompting authorities to ban 22 batches of the drug and order an inquiry.
Ask rediffGURU Naveenn Kummar your insurance mutual fund and personal finance-related questions.
Trump said California has been particularly "hard hit" because of this, blaming democrat Gavin Newsom, the Governor of California, for this loss, calling him "weak and incompetent."
India's pharmaceuticals and medical devices industries are still hopeful that trade negotiations with the US could cut a fairer deal for both sides, after President Donald Trump announced a 25 per cent tariff rate on India on a social networking platform without divulging the finer details.
The Indian pharmaceutical industry is likely to benefit from a major wave of patent expiries in the US, as small-molecule drugs worth $63.7 billion are expected to go off-patent between 2025-29, a 65 per cent rise over the previous five years, according to a report by Antique stock broking limited.
India, the land that gave the world Darjeeling and Assam tea, risks losing its place at the global tea table, not because of its leaves, but because of its lost opportunities, notes Kanika Datta.
'If we want to pivot meaningfully from a services-driven economy to a technology and manufacturing-led one.'
'Accordingly, no proprietary rights or exclusivity can be claimed over such a generic phrase, and any attempt to do so is legally unsustainable and contrary to the basic principles of trademark law.' According to the opposition, Mahendra Singh Dhoni's star power alone does not entitle him to monopolise a phrase that has historically described several athletes across generations.
Concerns over weakening demand for Indian pharmaceutical (pharma) drugs in the US - their largest export market - have weighed heavily on investor sentiment this year. While the Nifty 50 has gained 6.02 per cent year - to - date (as on September 15), the Nifty Pharma index has declined 5.18 per cent, National Stock Exchange data shows.
'Indian markets may underperform global peers for the next two quarters.' 'But beyond that, India should catch up and resume its long-term growth path.'
If it wasn't so violent, there would have been a few unintended laughs in Baaghi 4, but this one has not a shred of humour amidst the nonstop mayhem, observes Deepa Gahlot.
For a story about sweethearts and heartache, it's a pity that you will likely forget Love In Vietnam in a heartbeat, notes Mayur Sanap.
Ghaati does not understand how to harness Anushka Shetty's electrifying screen presence, complains Arjun Menon.
Inspector Zende had the potential to be genuinely entertaining. Instead, it settles for formulaic fun, observes Mayur Sanap.
Ask rediffGURU Naveenn Kummar your insurance mutual fund and personal finance-related questions.
If the 'Captain Cool' trademark goes through, it could trigger a wave of similar attempts by celebrities to trademark nicknames given to them by fans.
US accounts for a large part of revenue for top Indian pharma companies like Gland Pharma (54 percent), Dr Reddy's (53 per cent), and Aurobindo Pharma (48 per cent).
All doctors must prescribe generic drugs, failing which they will be penalised and even their license to practice may also be suspended for a period, according to the new regulations issued by the National Medical Commission (NMC).
The Delhi High Court has restrained Patanjali from running disparaging advertisements against Dabur Chyawanprash, following a plea by Dabur alleging that Patanjali's ads were disparaging their product and Chyawanprash in general.
Rising penetration of trade generic medicines is eating into the value growth of the domestic pharmaceutical market, showed a recent analysis. According to a Kotak Institutional Equities analysis, 70-110 basis points (bps) annual dent is expected from trade generics and Jan Aushadhi on Indian Pharma Market (IPM) growth at least until FY27-28 (see chart). Trade generic medicines are those that are not pushed into the market through doctor promotions.
India has not accepted the demand of the UK for inclusion of a 'data exclusivity' provision in the free trade agreement, announced on May 6, in a bid to protect the interests of the domestic generic drugs industry, an official said. During the negotiations, the UK had asked to include this provision in the trade pact.
'No one anticipated magical solutions or miraculous interventions.' 'However, people across the entire spectrum -- whether residing in the valley or the hills -- expected the prime minister to dedicate at least five to ten minutes to genuinely listening to the voice of the people.'
US President Donald Trump's plan to sign an executive order to cut prescription drug prices by 30-80 per cent could lead to a global price adjustment with pharma firms pushing lower-cost countries like India to raise prices, according to the economic think tank GTRI. The US move could push prices in lower-cost countries like India as manufacturers would seek to recover losses and R&D costs from these nations.
The restructuring of tariffs by the US has led to a shift in the list of key product suppliers to the American market, with India emerging as one of the beneficiaries at the expense of China and Canada, an official said on Monday. As per an analysis, India's share in the USA's electronics exports has increased to 7.2 per cent to 3.5 per cent year-on-year in May, while China's share dipped to 11 per cent from 22 per cent during the same period.
What keeps the momentum going is Kajol's fully committed performance that elevates this generic material to a surprising degree of watchability, feels Mayur Sanap.
'What India has done will surely embolden more countries to stand up to Trump.'
At the end of the day, this isn't about choosing between EMIs and SIPs. It's about choosing your path to financial freedom.
While most investors brush off NFOs like spam, some of them offer solid opportunities, especially when you know what to look for. So let's clear the confusion around NFOs and figure out when they're worth your money, and when they're not.
It looks like Diljit is having a field day with this one, one hopes his joy rubs off on viewers as well, notes Mayur Sanap.
Indian drugmakers supply 47 per cent of the generic medicine requirements in the US, and tariffs would have increased prices in the US domestic market for patients, who are already dealing with drug shortages.
Despite a healthy performance in the fourth quarter of 2024-25 (Q4FY25), the stock of India's largest listed pharma company, Sun Pharmaceutical Industries (Sun Pharma), was under pressure on Friday due to a muted guidance. The company has guided for a high single-digit revenue growth for FY26, which is below what the Street was working with.
India and the UK on Thursday inked a landmark free trade agreement (FTA) that will cut tariffs on British whisky, cars and an array of items, besides boosting bilateral trade by around $34 billion annually.
Trade generic drugs (medicines that are sold directly through distributors) are fast becoming a key segment for domestic pharma firms as volume growth slows in the overall market. Big companies like Cipla and Alkem have a significant presence in the segment but recently, players like Torrent Pharmaceuticals and Dr Reddy's Laboratories (DRL) have also entered this market. What is driving big pharma's focus on trade generics? The volume growth in the Indian Pharma Market (IPM) has come down from 5.6 per cent in FY16 to 0.1 per cent in FY23.
India is home to more than 100 million diabetics, and the demand for anti-diabetic drugs is on the rise -- the Rs 20,611 crore anti-diabetic drug market in India is growing at 9 per cent or so.
Ask rediffGURU and PF and MF expert Janak Patel your mutual fund and personal finance-related questions.
Chhal Kapat is a bland whodunnit, which does not have the necessary skills and smarts to pull it off, notes Mayur Sanap.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances